Strategic Focus Early stage biotechnology startup developing EA-230 immunomodulatory peptide, indicating potential partnerships in clinical research, regulatory consulting, and specialized manufacturing services to support development and scale.
Funding Readiness Receives about $11M in funding with current revenue under $1M, suggesting opportunities for grant advisory, CRO alignment, and milestone-based service offerings to accelerate product milestones.
Small Team, Niche Headcount is 0-1, implying a high potential need for outsourced clinical operations, regulatory affairs support, and contract manufacturing to enable rapid progression without building in-house capabilities.
Digital Footprint Tech stack includes WordPress, Shopify, Azure, and Nginx, indicating receptivity to cloud-based solutions, cybersecurity services, and scalable e-commerce or marketing integrations for investor relations and partner outreach.
Clinical Focus Product EA-230 is an intravenously administered immunomodulatory peptide derived from a human pregnancy hormone, presenting opportunities in partnering with contract research organizations, specialty pharma players, and clinics focused on immunology and pregnancy-linked therapeutics.